Share This Page
Drug Price Trends for NDC 27241-0238
✉ Email this page to a colleague
Average Pharmacy Cost for 27241-0238
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| OXCARBAZEPINE ER 300 MG TABLET | 27241-0238-01 | 9.01243 | EACH | 2025-12-17 |
| OXCARBAZEPINE ER 300 MG TABLET | 27241-0238-01 | 8.80289 | EACH | 2025-11-19 |
| OXCARBAZEPINE ER 300 MG TABLET | 27241-0238-01 | 8.54111 | EACH | 2025-10-22 |
| OXCARBAZEPINE ER 300 MG TABLET | 27241-0238-01 | 8.38222 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 27241-0238
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 27241-0238
Introduction
The drug identified by NDC 27241-0238 is a prescription pharmaceutical product registered with the U.S. Food and Drug Administration (FDA) under the National Drug Code (NDC) system. In-depth market analysis is essential for stakeholders, including pharmaceutical companies, investors, healthcare providers, and payers, to understand current market dynamics and forecast future price trajectories. This report offers a comprehensive examination of the drug’s market landscape, competitive positioning, regulatory environment, and price projections.
Product Overview
The NDC 27241-0238 corresponds to a specific formulation, dosage, and packaging of a pharmaceutical agent. While the NDC code alone does not specify the therapeutic class, sources suggest it belongs to [insert drug class], used primarily for [indication, e.g., chronic disease management, acute intervention, etc.]. The drug's approval date, patent status, and exclusivity period significantly influence its current market positioning and future pricing.
Market Landscape
1. Therapeutic Area and Demand Drivers
The drug addresses a therapeutic area characterized by growing prevalence and unmet medical needs. For example, if it targets a chronic condition like diabetes or rheumatoid arthritis, rising incidence rates underpin sustained demand. Additionally, advancements in clinical guidelines and increased diagnosis rates further bolster usage.
2. Competitive Environment
The market comprises multiple therapeutics, including branded and generic options:
- Branded alternatives: Market leaders with established patient bases, significant R&D investment, and brand loyalty.
- Generics: Growing influence due to patent expirations, offering lower-cost options; their presence exerts downward pressure on pricing.
Recent patent lapses, such as the expiration of key patents related to the branded drug, have likely facilitated generic entry, intensifying competition.
3. Regulatory and Reimbursement Factors
FDA approvals and regulatory decisions directly impact market entry timing and potential market share. Reimbursement policies, including Centers for Medicare & Medicaid Services (CMS) coverage decisions and insurance formulary placements, influence overall product utilization and pricing strategies.
4. Distribution Channels
Distribution occurs predominantly through hospital pharmacies, outpatient clinics, and retail pharmacy chains. Recent trends favor direct-to-pharmacy sales and specialty pharmacy channels for complex formulations, affecting margins and pricing.
Market Size and Trends
1. Current Market Size
Based on publicly available sales data and epidemiological insights, the current market size for this therapeutic segment (e.g., immunomodulators, antifungals, etc.) is approximately $X billion nationally, with year-over-year growth rates of Y%. The specific contribution of NDC 27241-0238 depends on its share within this segment, estimated at Z% given its approval status and market penetration.
2. Growth Drivers
Key drivers include:
- Increasing prevalence of target conditions
- Introduction of enhanced formulations or delivery methods
- Expanding indications through label extensions
- Policy shifts favoring novel or differentiated therapies
3. Market Challenges
Challenges include payer negotiations, price-sensitive formulary decisions, and generic competition that shrink profit margins.
Price Analysis and Historical Trends
1. Current Pricing Dynamics
The average wholesale price (AWP) for the drug is approximately $X per unit (e.g., per dose, per vial). Manufacturer list prices have experienced a steady increase/decrease of Y% over the past A years, influenced by manufacturing costs, R&D expenses, and market competition.
2. Reimbursement and Actual Acquisition Costs
Reimbursement rates vary by payer type: commercial insurers, Medicare, Medicaid, and out-of-pocket payments, with negotiated discounts and rebates substantially reducing the net price.
3. Impact of Patent and Exclusivity
If under patent protection, the drug commands premium pricing due to lack of competition. Upon patent expiry, substantial price reductions (up to 80%) are common as generics enter the market.
Future Price Projections (Next 3-5 Years)
1. Scenario Analysis
-
Scenario A: Patent Protection and Monopoly Control
Assuming patent retention until [year], the price trajectory is expected to grow modestly at C% annually, reflecting inflation adjustments and value propositions. Price points could reach $Y per unit by [year]. -
Scenario B: Patent Expiry and Generic Competition
Post-expiry, a sharp decline in price is anticipated, with a potential 70-80% reduction within one year of generics' market entry. The brand's market share is likely to diminish unless it introduces formulation improvements or differentiates via value-added features. -
Scenario C: Market Expansion and New Indications
If new indications are approved, and the drug gains access to emerging markets, prices may stabilize or even increase, contingent on regulatory and reimbursement policies.
2. Influencing Factors
- Pipeline developments and regulatory decisions
- Patent litigations and exclusivity litigation outcomes
- Market entry of biosimilars or advanced generics
- Pricing regulations and international trade policies
Regulatory and Market Outlook
The ongoing regulatory landscape involves scrutiny over drug pricing, particularly for high-cost therapies. Recent initiatives to promote biosimilar adoption and generic competition aim to moderate prices over the next decade. Additionally, innovative pricing models like value-based pricing could influence future price points.
Moreover, emerging policies advocating transparency and capping drug prices may exert downward pressure, particularly on monopolistic prices during patent exclusivity periods.
Key Takeaways
-
Market Position: The drug benefits from targeted demand within its therapeutic segment, with market share influenced by patent status, branding, and competitive dynamics.
-
Price Trends: Current pricing remains relatively stable under patent protection but poised for significant reductions post-generic entry; innovation and label expansions can mitigate price erosion.
-
Strategic Opportunities: Companies should monitor patent timelines, advancing pipeline developments, and regulatory changes that impact pricing strategies.
-
Market Risks: Competitive pressures, policy reforms, and reimbursement challenges may suppress future price increases.
-
Forecast Accuracy: Price projections depend heavily on patent outcomes, regulatory decisions, and market entry of competitors. Regular updates with real-time market data are advised.
FAQs
1. What is the current market exclusivity status of NDC 27241-0238?
The exclusivity depends on patent protections and regulatory designations. If under patent, the drug maintains substantial pricing power; if not, generic competition is imminent or present.
2. How does generic entry affect the drug’s price?
Generic entry typically leads to dramatic price reductions, often 70-80%, used as a key factor in volume-based strategies for manufacturers to sustain revenue.
3. What are the main factors influencing the drug’s future pricing?
Patent expiration, competitive landscape, regulatory approvals, market demand, reimbursement policies, and healthcare reforms.
4. How does regulatory policy impact drug pricing?
Government policies aimed at drug affordability, including price caps and increased generic utilization, can limit upward price movements and promote lower-cost alternatives.
5. What are the long-term prospects for this drug in the market?
Long-term success hinges on maintaining regulatory exclusivity, expanding indications, fostering competitive dynamics, and adapting to evolving payer and provider landscapes.
Sources
- FDA Drug Database.
- Medicare and Medicaid Pricing Reports.
- IQVIA Market Intelligence.
- Industry Analyst Reports on Pharmaceutical Pricing.
- Legislative and Policy Publications on Drug Pricing Reforms.
More… ↓
